Exelixis (EXEL) Cost of Revenue (2013 - 2026)
Exelixis (EXEL) recorded quarterly Cost of Revenue of $20.0 million in Q2 2026, down 24.65% quarter-over-quarter from $26.5 million in Q1 2026, and up 4.07% on a YoY basis from $19.2 million in Q2 2025.
Exelixis (EXEL) Cost of Revenue (2013 - 2026) Analysis & Trends
Exelixis' Cost of Revenue history runs 14 years deep, the most recent figure standing at $20.0 million for Q2 2026.
- In Q2 2026, Cost of Revenue rose 4.07% year-over-year to $20.0 million; the TTM figure through Apr 2026 stood at $84.5 million (up 13.96% YoY), while the FY2026 annual figure was $83.7 million, up 9.82% from the prior year.
- Cost of Revenue was $20.0 million for Q2 2026 at Exelixis, down from $26.5 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $26.5 million in Q1 2026 to a low of $13.2 million in Q2 2022.
- Historically, Cost of Revenue has averaged $18.3 million across 5 years, with a median of $18.6 million in 2025.
- The sharpest annual moves came in 2024 and 2025: Cost of Revenue surged 48.49% in 2024, then dropped 9.8% in 2025.
- A 5-year view of Cost of Revenue shows it stood at $15.9 million in 2022, then surged by 36.64% to $21.8 million in 2023, then declined by 20.34% to $17.3 million in 2024, then climbed by 7.19% to $18.6 million in 2025, then grew by 7.42% to $20.0 million in 2026.
- The last three Cost of Revenue figures came in at $20.0 million (Q2 2026), $26.5 million (Q1 2026), and $18.6 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 64.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 48,670.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 392.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 2.05 Mn |
| 10 | Exelixis | 13.61 Bn | 12.83 Bn | 590.86 Mn | 19.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 19.95 Mn |
| Apr 3, 2026 | 19.95 Mn |
| Jan 2, 2026 | 26.48 Mn |
| Jan 2, 2026 | 26.48 Mn |
| Oct 3, 2025 | 18.57 Mn |
| Oct 3, 2025 | 18.57 Mn |
| Jul 4, 2025 | 19.47 Mn |
| Jul 4, 2025 | 19.47 Mn |
| Apr 4, 2025 | 19.17 Mn |
| Apr 4, 2025 | 19.17 Mn |
| Jan 3, 2025 | 19.97 Mn |
| Jan 3, 2025 | 19.97 Mn |
| Sep 27, 2024 | 17.33 Mn |
| Sep 27, 2024 | 17.33 Mn |
| Jun 28, 2024 | 17.67 Mn |
| Jun 28, 2024 | 17.67 Mn |
| Mar 29, 2024 | 21.26 Mn |
| Mar 29, 2024 | 21.26 Mn |
| Dec 29, 2023 | 21.75 Mn |
| Dec 29, 2023 | 21.75 Mn |